J & J to acquire VC-backed Novira Therapeutics

By Iris Dorbian — 3 months ago

Johnson & Johnson has agreed to buy Novira Therapeutics Inc, a biopharmaceutical company focused on developing new treatments for chronic hepatitis B virus infection. No financial terms were disclosed for the deal that is expected to be completed during the fourth quarter of this year. Novira is backed by Versant Ventures, 5AM Ventures and Canaan […]

Continue

Crinetics scores $40 mln Series A

By Iris Dorbian — 3 months ago

San Diego, California-based Crinetics Pharmaceuticals, which is focused on treating specialty endocrine disorders, has closed $40 million in Series A financing. Versant Ventures, 5AM Ventures and Vivo Capital led the round. In addition to the funding, Dr. Wendell Wierenga has been named chairman of Crinetics’ board of directors. Also, Crinetics has appointed Dr. Mason Freeman of 5AM Ventures, Dr. Steve Kaldor of Versant Ventures and Dr. Mahendra Shah of Vivo Capital to its board of directors.

Continue

Turnstone rakes in $11.3 mln Series A in Versant-led round

By Iris Dorbian — 4 months ago

Turnstone Biologics Inc, a biotech company focused on developing novel oncolytic viral immunotherapies for cancer, has closed $11.3 million in Series A funding. Versant Ventures led the round. In addition to the funding, the company has named Dr. Sammy J. Farah as CEO and Dr. Brian D. Lichty as chief technology officer while adding Dr. Jerel Davis and Dr. Brad Bolzon, a partner and managing director at Versant Ventures respectively, to its board of directors.

Continue

Gritstone Oncology racks up $102 mln Series A

By Iris Dorbian — 4 months ago

San Francisco Bay area-based Gritstone Oncology, a cancer immunotherapy company, has raised $102 million in Series A financing. The investors included Versant Ventures, The Column Group, Clarus Ventures, Frazier Healthcare Partners, Redmile Group, Casdin Capital and Transformational Healthcare Opportunity.

Continue

Therachon fetches $35 mln Series A

By Iris Dorbian — 4 months ago

France-based Therachon, a developer of treatments for achondroplasia, has secured $35 million in Series A funding. OrbiMed led the round with participation from New Enterprise Associates, Inserm Transfer Initiative and Versant Ventures. In conjunction with the funding, Dr. Stephen Squinto, a venture partner at OrbiMed and Dr. Sara Nayeem, a principal at NEA, have been added to the board of directors.

Continue

NeuWave Medical scores $25 mln Series C

By Iris Dorbian — 9 months ago

Madison, Wisconsin-based medical device company NeuWave Medical Inc has closed $25 million in Series C financing. Versant Ventures led the round with participation from other investors that included H.I.G. BioVentures and Venture Investors. In conjunction with the funding, NeuWave has added Kirk Nielsen, managing director at Versant Ventures, to its board of directors.

Continue

VC-backed Glaukos Corp files for IPO

By Iris Dorbian — 9 months ago

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

Continue

Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO

By Iris Dorbian — 12 months ago

Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna’s board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.

Continue

Deerfield leads $42.5 mln round for Audentes

By Iris Dorbian — 1 year ago

San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes’ board of directors.

Continue

Versant places Mazzo on administrative leave following indictment

By Iris Dorbian — 1 year ago

Versant Ventures has placed operating partner Jim Mazzo on administrative leave following a federal grand jury indictment for alleged insider trading, a source at Versant confirmed. Both Mazzo and Versant have mutually agreed that Mazzo will suspend his work at the healthcare-focused venture firm until his legal matters are resolved.

Continue

Northleaf Capital holds second close on $233.5 mln for venture fund of funds

By Chris Witkowsky — 2 years ago

Northleaf Capital Partners has held a second closing on its Venture Catalyst Fund, bringing commitments to date to $233.5 million. The fund of funds, the first to be established under the Canadian government’s Venture Capital Action Plan, began investing in January and has made six investments, including three fund commitments to Versant Ventures, Georgian Partners and XPV Capital.

Continue